Actively Recruiting
Hemophagocytosis in Critically Ill Adult Patients
Led by University of Ulm · Updated on 2024-01-17
40
Participants Needed
2
Research Sites
700 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to find out whether non-responsiveness to therapeutic recombinant human granulocyte colony-stimulation factor (rhG-CSF) is associated with hemophagocytosis in critically ill adult patients with cytopenias.
CONDITIONS
Official Title
Hemophagocytosis in Critically Ill Adult Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years
- Critically ill adult patients
- Low white blood cell count (leukopenia) and low platelet count (thrombocytopenia)
- Receiving recombinant human granulocyte colony-stimulating factor (rhG-CSF) therapy
You will not qualify if you...
- Life expectancy less than 24 hours
- Participation in other studies
- Trauma patients who had reanimation on scene or died immediately upon hospital admission
- Pregnancy
- Hematologic disorders or malignancy
- Recent high-dose corticosteroid treatment or chemotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Anaesthesiology, University Hospital Ulm
Ulm, Germany, 89075
Actively Recruiting
2
Department of Internal Medicine III, Comprehensive Infectious Disease Center, University Hospital Ulm, Germany
Ulm, Germany, 89075
Actively Recruiting
Research Team
M
Manfred E Weiss, MD
CONTACT
E
Elisabeth M Schneider, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here